必赢电子

 
 
?Yinsong Wang, Professor
发布人:药必赢电子-英文  发布时间:2019-12-05   浏览次数:131

Yinsong Wang, M.D.


 

Yinsong Wang, MD

Professor

School of Pharmacy

Tianjin Medical University

22 Qixiangtai Road

Tianjin 300070

Phone: +86-22-83336658

Email: wangyinsong@tmu.edu.cn

 

Education

B.S.    Shenyang Pharmaceutical University, Shenyang, China, 1997

M.S.   Ocean University of China, Qingdao, China, 2003

M.D.  Chinese Academy of Medical Sciences & Pecking Union Medical College, Beijing, China, 2006

Postdoctoral Fellow Tianjin Medical University, Tianjin, China, 2012

 

Professional Experience

1997--2000     Assistant Engineer, Qingdao Haier Biological PharmaceuticalCo.,LTD, Qingdao, China

2006--2010     Instructor, School of Pharmacy, Tianjin Medical University, Tianjin, China

2011--2015    Associate Professor, School of Pharmacy, Tianjin Medical University, Tianjin, China

2015--            Professor, School of Pharmacy, Tianjin Medical University, Tianjin, China

 

Honors

1. TianjinScience and Technology Award (2nd class) in 2013

2. 11thFive New Century Talents of Tianjin Medical University

3. 13th Five Year and TMU talent project

 

Professional Service

 

Reviewer for:

Biomaterials

ACS Applied Materials & Interfaces

Journal of Controlled Release

Cancer Letter

Theranostics

International Journal of Nanomedicine

Nanotechnology

Carbohydrate Polymers

Drug Delivery

Polymer Chemistry

RSC Advances

Journal of Microencapsulation

 

Membership of Academic Society

Nano Oncology Professional Committee of Chinese Anticancer Association

Chinese Society for Biomaterials (CSBM)

The Youth Work Committee of Tianjin Pharmaceutical Association

 

 

Publication

 

1.      ZhangT, LiuH, LiY, Li C*, WanG, ChenB, LiC, Wang Yinsong*. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition. Acta Biomater, online doi: 10.1016/j.actbio.2019.09.001.

2.      Wan G, Cheng Y, Song J, Chen Q, Chen B, Liu Y,Ji S, Chen H*, Wang Yinsong*.Nucleus-targeting near-infrared nanoparticles based on TAT peptideconjugatedIR780 for photo-chemotherapy of breast cancer. Chem Eng J, 2020, 380: 122458. IF, 8.355

3.      Zhang S, Guo N, Wan G, Zhang T, Li C, Wang Y, Wang Yinsong*, Liu Y. pH and redox dual?responsive nanoparticles based on disulfide?containing poly (β?amino ester) for combining chemotherapy and COX?2 inhibitor to overcome drug resistance in breast cancer. J Nanobiotechnol, 2019, 17: 109. IF, 5.345

4.      Tian Z, Xu L, Chen Q, Feng R, Lu H, TanH,Kang J, Wang Yinsong*, Hua Yan*. Treatment of surgical brain injury by immune tolerance induced by peripheral intravenous injection of biotargeting nanoparticles loaded with brain antigens. Front Immunol, 2019, 10: 743. IF, 4.816

5.      Chen B, Zhang Y, Ran R, Wang B, Qin F, Zhang T,Wan G, Chen H,Wang Yinsong*. Reactive oxygen species-responsive nanoparticles based on a thioketal-containing poly (β-amino ester) for combining photothermal/photodynamic therapy and chemotherapy. Polym Chem, 2019, 10: 4746–4757. IF, 4.760

6.      Zhou P, Qin J, Zhou C, Wan G, Liu Y, Zhang M, Yang X, Zhang N*, Wang Yinsong*. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer. Biomaterials, 2019, 195: 86-99. IF, 10.273

7.      Wan G, Chen B, Li L, Wang D, Shi S, Zhang T, Wang Y, Zhang L, Wang Yinsong*. Nanoscaled red blood cells facilitate breast cancer treatment by combining photothermal/photodynamic therapy and chemotherapy. Biomaterials, 2018, 155: 25-40. IF, 10.273

8.      Shi S, Zhang L, Zhu M, Wan G, Li C, Zhang J, Wang Y*, Wang Yinsong*.  Reactive oxygen species-responsive nanoparticles based on PEGlated prodrug for targeted treatment of oral tongue squamous cell carcinoma by combining photodynamic therapy and chemotherapy. ACS Appl. Mater. Interfaces 2018, 10, 29260?29272. IF, 8.456

9.      Liu Y, Qiao L, Zhang S, Wan G, Chen B, Zhou P, Zhang N*, Wang Yinsong*. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater, 2018, 66: 310-324. IF, 6.638

10.  Zhang S, Wang Dan, Li Y, Li L, Chen H, Xiong Q, Liu Y*, Wang Yinsong*. pH- and redox-responsive nanoparticles composed of charge-reversible pullulan based shells and disulfide-containing poly(?-amino ester) cores for co-delivery of a gene and chemotherapeutic agent. Nanotechnology, 2018, 29: 325101. IF, 3.399

11.  Liu Y, Wan G, Guo H, Liu Y, Zhou P, Wang H, Wang D, Zhang S, Wang Yinsong*, Zhang N*. A multifunctional nanoparticle system combines sonodynamic therapy and chemotherapy to treat hepatocellular carcinoma. Nano Res, 2017; 10(3): 834–855. IF, 7.354

12.  Wang Y, Wan G, Li Z, Shi S, Chen B, Li C, Zhang L*, Wang Yinsong*. PEGylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma. Int J Pharm, 2017; 525: 21–31. IF, 3.862

13.  Liu X, Gao C, Gu J, Gao W, An T, Fu J, Wang Yinsong*, Yang X*. Hyaluronic acid stabilized iodine-containing nanoparticles with Au nanoshell coating for X?ray CT imaging and photothermal therapy of tumors. ACS Appl Mater Interfaces, 2016; 8: 27622 ?27631. IF, 7.504

14.  Zhang C, An T, Wang D, Wan G, Zhang M, Wang H, Zhang S, Li R, Yang X, Wang Yinsong*. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma. J Control Release, 2016; 226: 193 –204. IF, 7.786

15.  Wang H, Wan G, Liu Y, Chen B, Zhang N*, Wang Yinsong*. Dual-responsive nanoparticles based on oxidized pullulan and a disulfide-containing poly(β-amino) ester for efficient delivery of genes and chemotherapeutic agents targeting hepatoma. Polym Chem, 2016; 7, 6340–6353. IF, 5.375

16.  An T, Zhang C, Han X, Wan G, Wang D, Yang Z, Wang Y, Zhang L, Y Wang*. Hyaluronic acid-coated poly(b-amino) ester nanoparticles as carrier of doxorubicin for overcoming drug resistance in breast cancer cells. RSC Adv, 2016; 6: 38624–38636. IF, 3.108

17.  Wan G, Liu Y, Shi S, Chen B, Wang Y, Wang H, Zhang L, Zhang N*, Wang Yinsong*. Hematoporphyrin and doxorubicin co-loaded nanomicelles for the reversal of drug resistance in human breast cancer cells by combining sonodynamic therapy and chemotherapy. RSC Adv, 2016; 6, 100361–100372. IF, 3.108

18.  Wang Y, Liu Y, Liu Y, Zhou W, Wang H, Wan G, Sun D, Zhang N*, Wang Yinsong*. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. Int J Pharm, 2015; 483: 89–100. IF, 3.994

19.  Zhou P, An T, Zhao C, Li Y, Li R, Yang R, Wang Yinsong*, Gao X*. Lactosylated PLGA nanoparticles containing e-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins. Int J Pharm, 2015; 478: 633–643. IF, 3.994

20.  Ren Y, Wang R, Liu Y, Guo H, Zhou X, Yuan X, Liu C, Tian J, Yin H, Wang Yinsong*, Zhang N*. A hematoporphyrin-based delivery system for drug resistance reversal and tumor ablation. Biomaterials, 2014; 35: 2460–2470. IF, 8.557

21.  Liu Y, Wang Y, Zhang C, Zhou P, Liu Y, An T, Sun D, Zhang N*, Wang Yinsong*. Core-shell nanoparticles based on pullulan and poly(β-amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent. ACS Appl Mater Interfaces, 2014; 6: 18712–18720. IF, 6.723

22.  Wang Yinsong*, Liu Y, Liu Y, Wang Y, Wu J, Li R, Yang J, Zhang N*. pH-sensitive pullulan-based nanoparticles for intracellular drug delivery. Polym Chem, 2014, 5: 423–432. IF, 5.520

23.  Guo H, Liu Y, Wang Y, Wu J, Yang X, Li R, Wang Yinsong*, Zhang N*. pH-sensitive pullulan-based nanoparticle carrier for adriamycin to overcome drug-resistance of cancer cells. Carbohydr Polym, 2014; 111: 908–917. IF, 4.074

24.  Wang Yinsong*, Chen H, Liu Y, Wu J, Zhou P, Wang Y, Li R, Yang X, Zhang N*. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. Biomaterials, 2013; 34: 7181–7190. IF, 8.312

25.  Liu Y, Luo Y, Wu J, Wang Yinsong*, Yang X, Yang R, Wang B, Zhang N*. Graphene oxide can induce in vitro and in vivo mutagenesis. Scientific Reports, 2013; 3: e3469. IF, 5.078

26.  Wu J, Wang Yinsong*, Yang X, Liu Y, Yang J, Yang R, Zhang N*. Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells. Nanotechnology, 2012; 23: 355101. IF, 3.842

 

                      

Grant

Ongoing:

1.      National Natural Science Foundation of China (No. 81972903): Multifunctional red blood cells designed based on tumor-targeted oxygen supply and high penetration for treatment of triple-negative breast cancer through combining PTT/PDT and immunotherapy (2020.01--2023.12), project leader.

2.      Project of Young and Middle-aged Key Innovative Talents in Colleges and Universities of Tianjin (2017.09--2020.08), project leader.

3.      13th Five-year Talent Project of Tianjin Medical University (2016.01--2019.12), project leader.

4.      Key Project of Natural Science Foundation of Tianjin (18JCZDJC33400): A biomimetic nanocarrier system mediated by mixed membrane from leukocytes and platelets for targeted treatment of triple-negative breast cancer by combining photothermal/photodynamic therapy and immunotherapy (2018.04--2021.03), project leader.

5.    National Natural Science Foundation of China (No. 81573005):The design of multi-functional nano-therapeutic system for combination of sonodynamic therapy, chemotherapy and immunotherapy and the study of its targeted anti-hepatoma activities (2016.01--2019.12), project leader.

 

Completed:

1.    National Natural Science Foundation of China (No. 81371671):A dual-responsive drug delivery nanosystem for carrying and orderly releasing gene/chemotherapeutic drug and its liver-targeting anticancer effects (2014.01--2017.12), project leader.

2.    National Basic Research Program of China (the 973 Program, No. 2011CB933100): Early diagnosis of hepatocellular carcinoma based on nanotechnology. (2011.01--2015.12), key member.

3.    National Natural Science Foundation of China (No. 30900303):A pH-responsive drug delivery nanosystem for combination treatment on cancer (2010.01--2012.12), project leader.

4.    Special China Postdoctoral Science Foundation (No. 201104308): Pullulan-based pH-sensitive drug nanocarrier targeting cell nucleus for reversal of cancer drug resistance. (2012.01-2014.12), project leader.

5.    China Postdoctoral Science Foundation (No. 20100480654): pH-sensitive drug nanocarrier based on pullulan for overcoming cancer drug resistance. (2011.10-2013.10), project leader.






 
必赢电子【集团】股份有限公司